Post-traumatic stress disorder

Nexalin Technology Unveils Next-Generation HALO™ Clarity

Retrieved on: 
Thursday, January 11, 2024
Patient, TBI, Privacy, Research, PTSD, Post-traumatic stress disorder, History, Food, FDA, Physician, Traumatic brain injury, Chronic pain, MDD, Pharmaceutical industry

HOUSTON, TEXAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today unveiled its Gen-3 HALO™ Clarity 15 milliamp (mA) neurostimulation device designed to treat a variety of mental health conditions, including Major Depressive Disorder (MDD), addiction and substance use disorder, Alzheimer’s disease, traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), chronic pain and other potentially-applicable stress-related neuropsychiatric disorders.

Key Points: 
  • The HALO™ Clarity utilizes an advanced technique, Deep Intracranial Frequency Stimulation (DIFS™), to penetrate structures deep in the mid-brain that are associated with mental health disorders.
  • Nexalin believes that this innovative technique in its next-generation devices will generate enhanced patient therapeutic responses without adverse side effects.
  • The HALO™ Clarity device has been the subject of multiple clinical trials in China whose findings were published in medical journals.
  • Mark White, CEO of Nexalin Technology, stated, “The HALO™ Clarity marks a significant advance and possibly the most meaningful event in the history of the Company.

electroCore Expands Intellectual Property Portfolio

Retrieved on: 
Tuesday, January 9, 2024
United States patent law, Post-traumatic stress disorder, Patent, ElectroCore, Vagus nerve, PTSD, Meat

ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD).

Key Points: 
  • ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD).
  • U.S. Patent No.
  • 11,865,329 entitled “Vagal Nerve Stimulation for Treating Post-Traumatic Stress Disorder” generally relates to methods for treating the symptoms of post-traumatic stress disorder (PTSD) that include applying one or more electrical impulses transcutaneously to the vagus nerve for approximately 90 seconds to approximately 3 minutes.
  • The electrical impulses may comprise bursts of 2 to 20 pulses.

Bridging The Gap: Launch of BTL Addresses Mental Health Disparities This Black History Month

Retrieved on: 
Tuesday, January 9, 2024
Risk, Anxiety, Multimedia, Directory, Post-traumatic stress disorder, Mental health, Mental, Depression, Black Canadians, Nursing

HUNTSVILLE, ON, Jan. 9, 2024 /PRNewswire-PRWeb/ -- In response to the pressing mental health requirements within the Black community, the Black Therapist List in Canada has recently launched a comprehensive roster of Black therapists across Canada. The directory aims to make it easier for Black individuals to find culturally competent therapists who understand and can address their specific experiences and concerns.

Key Points: 
  • "We believe that everyone deserves access to quality mental health care that is culturally responsive and informed.
  • Our directory is a crucial resource for Black individuals seeking mental health support...we are proud to provide a safe and inclusive space for them."
  • - BTL Founder, Laurenne Samuel
    According to studies, Black individuals face unique and persistent mental health challenges, including a higher risk of depression, anxiety, and post-traumatic stress disorder.
  • "We need to prioritize the mental health of Black individuals, and this directory is a step towards addressing the disparities in access to mental health services.

Veterans Exploring Treatment Solutions (VETS) Grant Recipients Participate in Groundbreaking Stanford Study on Ibogaine Treatment for PTSD and TBI

Retrieved on: 
Friday, January 5, 2024
Psychiatry, Veteran, Post-traumatic stress disorder, TBI, Associate, Entrepreneurship, Trauma, United States Army, Deficit spending, Research, Depression, Ibogaine, Disability, Friends, Hope, Special operations, Environment, Stanford University, History, Anxiety, PTSD, Traumatic brain injury, Observational study, Sleep, Behavioural sciences, Suicidal ideation, Safety, Suicide, Life

CORONADO, Calif., Jan. 5, 2024 /PRNewswire-PRWeb/ -- Veterans Exploring Treatment Solutions (VETS), a leading non-profit organization dedicated to ending veteran suicide, shares the findings of a new groundbreaking study that it supported alongside Stanford University. The study, published today in Nature Medicine, is the first-of-its-kind observational study that captured the effects of ibogaine, the plant-based psychoactive drug, on veterans with Traumatic Brain Injury (TBI) and the debilitating consequences, including Post Traumatic Stress Disorder (PTSD).

Key Points: 
  • At one month following ibogaine treatment, the average rating improved to 5.1, equivalent to no disability.
  • The researchers also found a statistically significant reduction in suicidal ideation from participants, decreasing from 47% to 7% one month following treatment.
  • The study revealed that ibogaine therapy significantly reduced PTSD, anxiety, depression, and improved cognitive function in veterans with TBI.
  • Our collaboration with Stanford University and Dr. Williams is a major step forward in proving the potential of ibogaine for treating PTSD and TBI."

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Retrieved on: 
Thursday, January 4, 2024
IND, FDA, SILO, Columbia University, Investigational New Drug, GLP, PTSD, Animal, Post-traumatic stress disorder, Toxicity, Safety, Therapy, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The purpose of the study is to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range with the goal of bringing us closer to human trials.

Key Points: 
  • The purpose of the study is to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range with the goal of bringing us closer to human trials.
  • The six- to eight-week non-GLP study includes single ascending dose evaluation (phase 1) and a 7-day repeat intranasal dose toxicity and pharmacokinetic study.
  • In the first phase of the study, all of the animals appeared to tolerate the intranasal dosing procedure well, with minimal struggling and no sneezing observed.
  • Eric Weisblum, Chief Executive Officer of Silo Pharma, commented “There have been no adverse clinical observations reported to date for this study, which began in late November 2023 and will conclude in first quarter 2024.

GrayMatters Health Launches New FDA-Cleared Self-Neuromodulation PTSD Therapy in the United States

Retrieved on: 
Thursday, January 4, 2024
Magnetic resonance, Trauma, Abuse, EEG, Assault, Research, FDA, Psychotherapy, Amygdala, Trial of the century, Computer simulation, PTSD, Post-traumatic stress disorder, GMH, Patient, ARC, Neuropsychiatry, SOC, EFP

HAIFA, Israel, Jan. 4, 2024 /PRNewswire/ -- GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental health care, announces the official launch of Prism for PTSD in the United States. Prism for PTSD is currently being used to treat patients at two centers, with additional clinics in various phases of readiness.

Key Points: 
  • Prism for PTSD Digitizes Brain Activity Associated with PTSD, Giving Patients Skills to Address Symptoms
    HAIFA, Israel, Jan. 4, 2024 /PRNewswire/ -- GrayMatters Health (GMH) , developer of digital self-neuromodulation therapies for mental health care, announces the official launch of Prism for PTSD in the United States.
  • Prism for PTSD is currently being used to treat patients at two centers, with additional clinics in various phases of readiness.
  • 13 million Americans struggle with post-traumatic stress disorder (PTSD) following assault, abuse, military combat, illness, accident, or natural disasters.
  • Prism for PTSD utilizes an amygdala-based biomarker since research has shown that PTSD is associated with hyper-activity of the amygdala.

Veteran Heals Mind and Body Through Wounded Warrior Project Adaptive Cycling

Retrieved on: 
Wednesday, January 3, 2024
Veteran, TBI, Injury, Life, Social support, Wounded Warrior Project, WWP, Press release, Shoe, Post-traumatic stress disorder, Traumatic brain injury, Exercise, Environment, Nursing

Mark, though fortunate, suffered a severe traumatic brain injury (TBI), mild paralysis, and over two dozen broken bones.

Key Points: 
  • Mark, though fortunate, suffered a severe traumatic brain injury (TBI), mild paralysis, and over two dozen broken bones.
  • His unexpected path to healing came through adaptive cycling with Wounded Warrior Project® (WWP) Soldier Ride® .
  • Experience the interactive Multimedia News Release here: https:// www.multivu.com/players/English/9198751-wounded-warrior-project-soldier-...
    "I first met Wounded Warrior Project when an outreach coordinator came to visit me in the hospital, and he was an amputee," Mark shared.
  • The multi-day adaptive cycling event empowers warriors by increasing skills, building confidence in achieving goals, and connecting with their communities and each other.

A brief history of drug-fuelled combatants

Retrieved on: 
Tuesday, January 2, 2024
Veteran, Methylphenidate, Hallucinogen, Cardiac arrest, Euphoria, Hyoscyamus niger, DSM-IV codes, Death, Drinking, Student, Depression, Pyridoxine, Pain, Weight loss, Psilocybin, Psychotherapy, Ketamine, Nazism, Injection, Nicotine, Adderall, Aggression, Post-traumatic stress disorder, Beer, Human, MDMA, Stroke, Technology, Methamphetamine, LSD, Anxiety, World war, PTSD, Hallucination, Water, Piracetam, Food, Paranoia, Caffeine, Sleep, B6, Hyoscyamus, War, Amanita, Modafinil, Fenethylline, Life, Pharmaceutical industry

I don’t know whether he thought that it might reduce pain or improve performance, but the idea of taking drugs before “going into battle” goes back to the beginning of recorded history.

Key Points: 
  • I don’t know whether he thought that it might reduce pain or improve performance, but the idea of taking drugs before “going into battle” goes back to the beginning of recorded history.
  • Indeed, we find frequent mentions of mead drinking by the warriors in Edinburgh in the seventh-century epic poem The Goddodin.
  • These ancient warriors probably used alcohol to reduce anxiety and blunt the horrors they would face on the battlefield.
  • Pervitin (methamphetamine) was given almost freely to all arms of the German war machine.
  • The frontline Nazis called them Panzerschokolade (tank chocolate), due to the feelings of incredible strength and invincibility that the pills gave them.

Behavioural effects


The types of drugs taken by warriors can be lumped into three broad categories: depressants, hallucinogens and stimulants. Alcohol is a depressant that calms the nerves by reducing brain activity. Psychedelic mushrooms such as Amanita muscaria contain a variety of psychoactive substances. Hyoscyamus niger also has a variety of active compounds that cause hallucinations and, importantly, aggressive and combative behaviour.

  • The word “groggy” meaning dazed and unsteady came from British navy sailors exhibiting this behaviour after their daily ration of rum and water (grog).
  • The stimulants, but especially methamphetamine, would also lead to significant weight loss even after only a few days of use.
  • Long-term use, as we saw with the Nazis, would probably lead to emaciated soldiers.

Smart drugs

  • We have seen that soldiers take drugs before battles to calm nerves, deal with the horrors, reduce pain, tolerate lack of food and sleep and improve alertness.
  • The stimulants include drugs such as amphetamine salt mixtures, methylphenidate and modafinil, while nootropics include piracetam, caffeine, cobalamin (vitamin B12), guarana, pyridoxine (vitamin B6) and vinpocetine.
  • The integration of humans, technology and machines is thought to be the future of warfare and drugs that facilitate this are undoubtedly being researched by the military.

Post-traumatic stress disorder

  • There is a long history of soldiers taking alcohol and other drugs to deal with the horrors of what they have seen, or the disappointment of life after leaving the army.
  • These veterans are taking MDMA and psilocybin on doctors’ orders as part of their treatment for PTSD.
  • Ketamine is useful for treating depression and LSD is also being tested for various psychiatric disorders.


Colin Davidson has previously received funding from the US National Institute on Drug Abuse (NIDA). He is a consultant with the Defence Science and Technology Laboratory (UK).

MAPS PBC Announces New American Medical Association CPT III Codes for Psychedelic-Assisted Therapies Take Effect

Retrieved on: 
Tuesday, January 2, 2024
Continuity, Food, Priority review, Breakthrough therapy, Physician, MAPS, FDA, Intervention, Psychotherapy, NDA, SAN, MDMA, Mental health, PTSD, American Medical Association, Post-traumatic stress disorder, DEA, CPT, Safety, Pharmaceutical industry

SAN JOSE, Calif., Jan. 2, 2024 /PRNewswire/ -- MAPS Public Benefit Corporation ("MAPS PBC"), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced that the American Medical Association ("AMA") current procedural terminology ("CPT") III codes for psychedelic-assisted therapies, first announced in July 2023, are now in effect. The new CPT codes will provide physicians and other qualified healthcare providers a means to seek coverage and reimbursement for delivering psychedelic-assisted therapy if approved by the U.S. Food and Drug Administration ("FDA").

Key Points: 
  • SAN JOSE, Calif., Jan. 2, 2024 /PRNewswire/ -- MAPS Public Benefit Corporation ("MAPS PBC"), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced that the American Medical Association ("AMA") current procedural terminology ("CPT") III codes for psychedelic-assisted therapies, first announced in July 2023, are now in effect.
  • MAPS PBC and COMPASS Pathways collaborated to work with the AMA to create these new CPT III codes.
  • On March 3, 2023, the AMA published the Summary of Panel Actions which included the acceptance of the new CPT III codes.
  • With Breakthrough Therapy designation given to MDMA in 2017, MAPS PBC has requested the FDA grant Priority Review of the NDA.

Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications

Retrieved on: 
Tuesday, January 2, 2024
Partnership, Post-traumatic stress disorder, Mental health, Depression, Research, WHO, Major depressive disorder, Therapy, PTSD, Bangladesh Technical Education Board, World Health Organization, MDD, Patient, Veterans' affairs, CKD

NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein.

Key Points: 
  • NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein.
  • CKD Bio is a subsidiary of Chong Kun Dang group based in Seoul, South Korea.
  • Healis Therapeutics intends to develop CKDB-501 for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).
  • “Our collaboration with CKD Bio on this new agreement could one day impact over 42 million Americans” said Sebastian De Beurs, Co-Founder of Healis.